The @SirenBio team is headed to #Boston this week for Cell & Gene Therapy International @CellTherapyIC! Catch Nathalie Clement and Lauren Kelly on Friday, when they’ll be sharing a behind-the-scenes glimpse of the CMC and nonclinical strategy that led to Siren’s first IND. Don’t miss it!

We’re excited to attend the Cell and Gene Therapy Symposium co-hosted by @UCSD, @CALifeSciences, and @CIRMnews! Our CEO, @Nicole, will be sharing the latest developments at @SirenBio and how we’re advancing #AAV Immuno #GeneTherapy to the clinic. Register & learn more below!👇 genetherapy.ucsd.edu/symposi…

We are thrilled to welcome Mary Bearkland, Senior Director of Clinical Operations, to the @SirenBio team! Mary brings more than 25 years of clinical operations leadership, having directed Phase I–III trials from first-in-human studies to regulatory submission and contributed to two FDA-approved therapies. She will lead our clinical operations as we advance SRN-101, our Universal #AAV Immuno #GeneTherapy, through the clinic. Welcome to the team, Mary!

🎉 Congratulations to Christine Xie on wrapping up a successful summer internship at @SirenBio! Christine, a student at @Stanford, spent the summer generating business development materials that guide Siren's strategic positioning as we advance our Universal #AAV Immuno #GeneTherapy for #Cancer. Her work will continue to serve the team long after her last day. Please join us in congratulating Christine and wishing her all the best as she heads back to Stanford this fall!

September is #ChildhoodCancerAwarenessMonth, and @SirenBio is thinking of every child and family facing a cancer diagnosis. Every step we take to advance Universal #AAV #GeneTherapy for #Cancer is for the patients and families who need better options. Let's sound the alarm against #cancer! #GoldSeptember #GoGold

On #GBMDay 2026, we're thinking of every patient and family living with this disease, and are committed to getting SRN-101 to the people who need it. Let's sound the alarm against #cancer!

📣 BIG news to close out the week! @SirenBio has been awarded an $8M non-dilutive CLIN2 grant from @CIRMnews to support our Phase 1/2 clinical trial of SRN-101 in adult recurrent high-grade glioma! We're incredibly grateful to CIRM and the vision and support of all Californians. Let's sound the alarm against #cancer! Read the press release: globenewswire.com/news-relea…

On #WorldBrainTumorDay, @SirenBio stands with every patient and family living with a brain tumor. Brain tumors like high-grade glioma are among the hardest cancers to treat, and that urgency drives everything we do. We're advancing SRN-101, our #AAV Immuno #GeneTherapy for high-grade glioma, to the clinic for patients who need it most. Let's sound the alarm against #cancer!

As #GrayMay comes to a close, we're reminded of why we show up every day at @SirenBio. High-grade gliomas are among the hardest cancers to treat. Survival is still measured in months for most patients, and meaningful new options have been slow to arrive. There are now two open INDs for SRN-101, our lead asset in recurrent high-grade glioma, and every step forward is motivated by the patients, families, and caregivers facing this disease head-on. Let's sound the alarm against cancer. #GrayMay #BrainTumorAwarenessMonth #GeneTherapy #Cancer

Our team had a wonderful time connecting with collaborators and fellow #AAV #GeneTherapy experts last week at #ASGCT2026! Highlights were talking great science at our annual Siren happy hour and presenting some of our large animal and CMC data. Missed our poster and talk? Check them out on our website: sirenbiotechnology.com/publi…

@SirenBio is headed to #ASGCT2026 next week! Find us at the events below to learn more about our path to the clinic with #SRN101, our lead AAV immuno #genetherapy for #cancer. See you in Boston! Happy Hour RSVP: luma.com/kl56nvvt

BIG moment for @SirenBio 🚨 We’re thrilled to share that our first peer-reviewed manuscript is now published in @CellPressNews Molecular Therapy Oncology - and we’re heading to @ASGCTherapy 2026 with even more data to share! This publication showcases the foundation of our Universal AAV Immuno-Gene Therapy platform, including groundbreaking preclinical data in high-grade glioma, one of the toughest cancers with the greatest unmet need. Huge thanks to our team and collaborators for supporting this work! 👉 Read the full press release here: sirenbiotechnology.com/siren… 👉 Access the open access manuscript here: cell.com/molecular-therapy-f… Want more, like our IND large animal data?! Come find us at #ASGCT2026! #AAV #GeneTherapy #Immunotherapy #Oncology #Publication

Join @SirenBio's CEO @Nicole_Paulk and other industry leaders at the NORD Scientific Symposium next week! We’ll be sharing ways to bring community members in as company stakeholders through community fundraising. Register here: nordscience.org/

Thrilled to see @SirenBio SAB member Beverly Davidson recognized with the Outstanding Achievement Award by @ASGCTherapy! A well-deserved honor celebrating her pioneering work and lasting impact on the field 🌟

Big news for SRN-101 🚀 The FDA has cleared a second IND to launch a Phase 1 trial with SRN-101 in recurrent high-grade glioma. This investigator-initiated study, led by Dr. Nicholas Butowski at @UCSF, marks an exciting step forward in expanding clinical evaluation of SRN-101. We’re so proud to support the UCSF team as they advance this important work for patients in need! Learn more: sirenbiotechnology.com/Siren…

On the heels of IND clearance for SRN-101, we are thrilled to announce another major milestone at @SirenBio! 🚀 The FDA has granted #FastTrack Designation to SRN-101, our lead Universal #AAV Immuno-Gene Therapy candidate for recurrent high-grade glioma 🧠 Fast Track status reinforces the urgency and potential impact of bringing this first-of-its-kind therapy to patients. Momentum is building and we’re just getting started! 💥

The @SirenBio team is heading to Phacilitate #ATW26 next week. Our Founder & CEO, @Nicole_Paulk, and our SVP of Vector Development Nathalie Clement look forward to meeting with partners, peers, and fellow leaders pushing the field forward. If you’ll be in San Diego, we’d love to see you!

A big day of celebration here at @SirenBio! 🎉 We’re thrilled to share that the FDA has cleared our first IND for SRN-101, enabling our Phase I/II trial of what we believe is the first #AAV #GeneTherapy for any #cancer clinically. This milestone marks a major step forward in bringing SRN-101 to patients with recurrent high-grade glioma. Huge congratulations to our incredible team, advisors, and partners who helped make this moment possible!

It’s a busy start to 2026 at @SirenBio! We’re excited to be out in full force at #JPM2026, #ATW2026, and #BiocomGPIC. Come meet with us at: 📍 JPM Jan 12-15 | San Francisco, CA 📍 Advanced Therapies Feb 9-12 | San Diego, CA 📍 Biocom Feb 24-26 | La Jolla, CA If you’ll be there too, let’s connect!

Happy holidays from the @SirenBio team!🎄Our key moments were submitting our first IND to the FDA (today!) and closing our first-ever community investment round. But these can’t overshadow all the other accomplishments our team had in 2025. In all, we counted: ⚡ 8 new cancer indications tested 💸 1,529 new investors ✍️ First IND filed 🧠 3 new SAB members 🧪 10 formal assay qualifications 🏅 3 big awards received 🧬 100+ new constructs screened 💪 1 cancer diagnosis AND recovery! 💼 7 conferences attended 🐣 1 new baby 📆 50 weekly syncs and 26 lab meetings 🥹 1 proud team with ♾️ accomplishments…make that ♾️ + 1! 💛 Stay tuned for our 2026 tally…